6
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T40341 | SARS-CoV-2-IN-11 | ||
SARS-CoV-2-IN-11 is a highly potent and non-toxic inhibitor of the 3C-like protease (3CLpro) of SARS-CoV-2, demonstrating IC50 and EC50 values of 0.17 nM and 1.45 nM, respectively. This compound targets the essential vir... | |||
T72313 | SARS-CoV-2 3CLpro-IN-11 | ||
SARS-CoV-2 3CLpro-IN-11(11d) is a broad-spectrum antiviral compound that effectively inhibits the SARS-CoV-2 3CL protease, achieving an IC50 of 140 nM. Additionally, it exhibits inhibitory activity against SARS-CoV-1 and... | |||
T60818 | SARS-CoV-2-IN-15 | ||
SARS-CoV-2-IN-15 (compound 11) is a niclosamide analogue that contains higher stability in human plasma and liver S9 enzymes assay than niclosamide. It improves bioavailability and half-life when administered orally. SAR... | |||
T71191 | Covidcil-19 | ||
Covidcil-19 binds to the revised attenuator hairpin structure of the SARS-CoV-2 frameshifting element (FSE) with high affinity (Kd = 11 nM). It stabilizes the hairpin's folded state and reduces frameshifting efficiency i... | |||
T76849 | Bamlanivimab | ||
Bamlanivimab, an Anti-Human SARS-CoV-2 monoclonal antibody (mAb), was the first of its kind to receive Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) in November 2020 for COVID-19 trea... | |||
T38174 | Mpro inhibitor N3 hemihydrate | ||
Mpro inhibitor N3 hemihydrate is a potent antagonist of the SARS-CoV-2 main protease (Mpro), demonstrating an EC50 of 16.77 μM against SARS-CoV-2. It exhibits specific inhibition of Mpro in a range of coronaviruses, incl... |